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A B S T R A C T
Background
Partial onset seizures are often treated with the standard antiepileptic drug carbamazepine. Oxcarbazepine is a newer antiepileptic drug
related to carbamazepine that is claimed to be better tolerated.
Objectives
To compare efficacy and tolerability of carbamazepine and oxcarbazepine monotherapy for partial onset seizures.
Search methods
We searched the Cochrane Epilepsy Group Specialised Register (4 August 2009), the Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library issue 3, 2009), MEDLINE (January 1966 to May 2008), reference lists of relevant articles and
conference proceedings. We also contacted manufacturers and researchers in the field for published or unpublished data.
Selection criteria
Blinded and unblinded randomised controlled trials of carbamazepine versus oxcarbazepine monotherapy for partial onset seizures.
Data collection and analysis
Both authors independently assessed trial quality, according to the guidelines in the Cochrane Reviewer’s Handbook, and extracted
information about study population, type of intervention, outcome measures and study design. All analyses in this review are by
intention-to-treat. We tested for statistical heterogeneity among the identified studies using the chi-squared test.
Main results
Three trials (723 participants) were included. Only one trial used adequate outcomemeasures of efficacy; therefore, the results pertaining
to efficacy are based on a single trial, whereas the results pertaining to adverse events are based on all three included trials. There
was no overall difference in time to treatment withdrawal between the two drugs (hazard ratio (HR) of oxcarbazepine (OXC) versus
carbamazepine (CBZ): 1.04, 95% confidence interval (CI) 0.78 to 1.39). Further analyses showed no significant difference in treatment
withdrawal for unacceptable side effects (HR of OXC versus CBZ: 0.85, 95% CI 0.59 to 1.24) and in treatment withdrawal for
inadequate seizure control (HR of OXC versus CBZ: 1.33, 95% CI 0.82 to 2.15). Oxcarbazepine and carbamazepine appeared to be
similarly effective and well tolerated although the confidence intervals around estimates were wide and do not rule out the possibility of
important differences existing. Significantly fewer patients on carbamazepine treatment developed nausea or vomiting, or both (odds
ratio of OXC versus CBZ: 3.15, 95% CI 1.39 to 7.14).
1Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Authors’ conclusions
Oxcarbazepine and carbamazepine appear to be similarly effective and well tolerated. However, the possibility of important differences
existing between these drugs cannot be ruled out.
P L A I N L A N G U A G E S U M M A R Y
Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Carbamazepine is the most commonly used drug to treat partial epileptic seizures. Oxcarbazepine is a newer drug that was developed
with the intention to be as effective as carbamazepine but to cause fewer side effects. In this systematic review, we summarise three
studies in which oxcarbazepine and carbamazepine treatment were compared directly. We found that both drugs appear to be equally
effective and to cause side effects equally often. Significantly fewer patients on carbamazepine developed nausea or vomiting during
treatment.
B A C K G R O U N D
It is common clinical practice to treat patients with partial onset
seizures with the well established antiepileptic drug carbamazepine
(CBZ). Oxcarbazepine (OXC) is a newer antiepileptic drug de-
rived from CBZ with the intention to reduce side effects and drug
interactions, while maintaining equal efficacy. It has been claimed
thatOXCcauses fewer side effects and fewer allergic reactions than
CBZ (Shorvon 2000; Tecoma 1999).
Another theoretical advantage of OXC is a difference in the
metabolism of the two drugs. CBZ is metabolised via the hepatic
cytochrome-P450 enzyme system, and leads to an increase in the
expression (induction) of these enzymes (Schmidt 2004). OXC
on the other hand does not induce changes in this enzyme system
and, thus, may theoretically cause fewer drug interactions.
It is currently unknown whether these theoretical considerations
have any relevant clinical consequences and whether treatment
decisions should be based on them. In this systematic review, we
examine randomised trials comparing the two drugs with regard
to efficacy and tolerability.
O B J E C T I V E S
To compare the efficacy and tolerability of OXC and CBZ when
used as monotherapy for the treatment of partial onset seizures.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled monotherapy trials comparing OXC and
CBZ. The trials may be double-blinded, single-blinded or un-
blinded.
Adequately randomised and quasi-randomised trials are included,
non-randomised trials are excluded. Trials including patients with
intractable epilepsy awaiting epilepsy surgery are excluded.
An effort is made to include individual patient data if available.
Types of participants
Children and adults with all forms of partial onset seizures (simple
partial, complex partial, or partial onset seizures with secondary
generalisation).
Types of interventions
OXC or CBZ monotherapy.
Types of outcome measures
Primary outcome measure
The primary outcome measure is time from randomisation until
withdrawal of allocated treatment (retention time). The allocated
treatment may have been withdrawn due to unacceptable adverse
events, inadequate seizure control or the use of additional add-on
treatment. This is a combined outcome measure which encom-
passes efficacy as well as tolerability (Commission 1998).
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Secondary outcome measures
• Time to 12-month remission from seizures.
• Time to first seizure post-randomisation.
• Adverse events: any adverse event attributed to the drug in
question.
Search methods for identification of studies
We conducted a systematic literature search to identify all pub-
lished and unpublished randomised controlled trials.
Electronic searches
We carried out electronic searches, without language restrictions,
of:
(a) the Cochrane Epilepsy Group Specialised Register (last
searched 4 August 2009);
(b) the Cochrane Central Register of Controlled Trials (CEN-
TRAL, The Cochrane Library issue 3, 2009) (please see Appendix
1 for details of search strategy used);
(c) MEDLINE (from January 1966 until May 2008) (please see
Appendix 2 for details of search strategy used).
Searching other resources
(1) Reference tables of identified studies.
(2) Published abstracts of conference proceedings were hand-
searched.
(3) Personal communication with authors of identified studies and
other researchers in the field.
(4) Contact with the manufacturers of OXC and CBZ.
Strategies (3) and (4) were used to ascertain unpublished or ongo-
ing studies.
Data collection and analysis
Selection of studies
Both authors assessed independently the titles and abstracts of the
publications identified by the search strategy for possible inclusion.
The full text was selected for further assessment if the abstract
suggested relevance. Papers not meeting the inclusion criteria are
listed with the reason for omission. We resolved disagreements by
discussion.
Data extraction and management
We extracted information about study population, type of inter-
vention, outcome measures and study design from selected studies
independently on a data extraction form, then entered these data
into an electronic database (Review Manager 5).
Assessment of risk of bias in included studies
We evaluated the methodological quality of the studies according
to the guidelines in the Cochrane Reviewer’s Handbook (Higgins
2008).
Measures of treatment effect
All analyses in this review are by intention-to-treat.
Time-to-event data:
Cox regression model hazard ratios (HR) with their 95% confi-
dence intervals (CI) are given. If results from several studies had
been obtained, we would have performed a meta-analysis with the
fixed-effect general inverse variance method.
Number of adverse events:
For the comparison of the number of adverse events between CBZ
and OXC, odds ratios (OR) with their 95% CI are given. The
studies were summarised using the Mantel-Haenszel fixed-effect
model, and the OR was used as summary statistic.
Assessment of heterogeneity
We tested for statistical heterogeneity among the identified studies
using the chi-squared test. If significant heterogeneity between
studies had been found, we would have changed our method of
meta-analysis to using the random-effects model.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Five studies met our inclusion criteria (Dam 1989; Dizdarer 2000;
Donati 2007; Marson 2007; Reinikainen 1987).
Included studies
The Standard and New Antiepileptic Drugs (SANAD) trial (
Marson 2007) randomised a total of 1721 patients with epilepsy
to either CBZ (378), gabapentin (377), lamotrigine (378), OXC
(210), or topiramate (378). The inclusion criteria stated that pa-
tients had to have a history of two or more definite unprovoked
epileptic seizures in the year previous to randomisation and that
CBZ was deemed the better standard treatment option, compared
to valproate, by the recruiting physician. Patients were excluded if
all their seizures had been acute symptomatic seizures, if they were
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four years of age or younger, or if there was a history of progressive
neurological disease. Drug titration, initial maintenance dose and
any increments or decrements were decided by the clinician, just
as in everyday practice, aided by guidelines. Patients were seen
for follow-up at 3, 6 and 12 months, and at successive yearly in-
tervals from the date of randomisation. Occurrence of seizures,
adverse events and hospital admissions were documented. When
patients ceased visiting the hospital clinics, follow-up was done by
the general practitioner or by a telephone interview. The SANAD
trial was the only included trial using the same efficacy measures
we selected for this review. Therefore, the analyses on efficacy are
based solely on this trial.
Donati and coworkers (Donati 2007) performed an unblinded
trial on the effect of three antiepileptic drugs on cognition in chil-
dren and adolescents and randomised a total of 112 patients to ei-
therOXC (n = 55), CBZ (n = 28) or valproate (n = 29). Drug titra-
tion, initial maintenance dose and any increments or decrements
were decided by the clinician, just as in everyday practice, aided by
the prescribing information for the drug in question. Patients were
followed for six months. Outcomes regarding cognition were the
difference in performance in the Computerised Visual Searching
Task and several additional measures of psychomotor speed, alert-
ness, memory, learning and non-verbal intelligence. Further out-
comes were the number of patients remaining seizure free during
follow-up and the number of adverse events. The percentage of
patients remaining seizure free during follow-up was comparable
between the OXC group (32 of 55 patients (58%) seizure free)
and CBZ group (13 of 28 patients (46%) seizure free). Since the
efficacy outcome used in this trial differed from those we selected
for this review, and in view of the relatively short duration of the
trial, we decided not to seek individual patient data for inclusion
in time-to-event regression models but limited our analyses to the
adverse events data from this trial.
One trial including 52 children with partial epilepsy had been
published in abstract form (Dizdarer 2000). Children up to the
age of 15withmore than twopartial onset seizureswere included in
this trial. Patients with a structural brain lesion were excluded from
the study. The trial was unblinded and had two treatment groups.
After randomisation, patients received either CBZ in increasing
doses to 20 mg/kg/day after three to four days, or OXC to 30
mg/kg/day after three to four days. Patients were assessed at 1,
2 and 3 weeks, and 1, 3, 6, 9 and 12 months after initiation of
treatment. A diary, completed by the patients and their parents,
was applied to monitor side-effects. The mean follow-up period
was 15.4 months in the CBZ group and 15.6 months in the OXC
group. The outcomes in this study were the number of patients
remaining seizure-free during follow-up and the number of adverse
events. For this trial, individual patient data on efficacy measures
were no longer available, but data on adverse events were provided
by the study authors.
Excluded studies
Two studies (Dam 1989; Reinikainen 1987) included patients
with primary generalised as well as partial epilepsy. The percent-
age of patients with partial seizures was only 38% in one study
(Reinikainen 1987) and not specified in the other (Dam 1989).
These two trials also used outcome measures that differed from
those we selected for this review. Our attempt to acquire indi-
vidual patient data from the trial authors and sponsoring drug
companies failed, either because the data were no longer available
(Reinikainen 1987) or because we received no answer to our re-
quest from the sponsoring drug company (Dam 1989).
Risk of bias in included studies
Allocation
In two trials (Donati 2007; Marson 2007) participants were al-
located to treatment by a central randomisation centre, that used
a computer program for randomisation. In the study by Marson
and co-workers, fewer patients were randomised toOXC since this
drug was only later included in randomisation. The study by Do-
nati and colleagues used an allocation scheme for OXC, CBZ and
valproate of 2:1:1, and thus randomised fewer patients to CBZ.
The trial by Dizdarer et al. (Dizdarer 2000) used a quasi-randomi-
sation technique: patients were alternately allocated to CBZ or
OXC.
Blinding
All included trials were unblinded.
Effects of interventions
Time to treatment withdrawal
For this outcome measure, a HR greater than 1 suggests an advan-
tage for CBZ.
Only data of the SANAD trial (Marson 2007) were available for
the analysis of this outcome. There was no overall difference in
time to treatment withdrawal between the two drugs (HR 1.04,
95% CI 0.78 to 1.39 Analysis 1.1; Figure 1). Further analyses by
the cause of treatment withdrawal also showed no significant dif-
ference between the two drugs (Treatment withdrawal for unac-
ceptable side effects HR 0.85, 95% CI 0.59 to 1.24 Analysis 1.2;
Figure 2; and Treatment withdrawal for inadequate seizure control
HR 1.33, 95% CI 0.82 to 2.15 Analysis 1.3; Figure 3).
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Figure 1. Comparison OXC versus CBZ, Outcome 01 Time to treatment withdrawal for any reason.
Figure 2. Comparison OXC versus CBZ, Outcome 02 Time to treatment withdrawal for unacceptable
adverse events.
Figure 3. Comparison OXC versus CBZ, Outcome 03 Time to treatment withdrawal for inadequate
seizure control.
Time to 12-month remission from seizures
For this outcome measure, a HR greater than 1 suggests an advan-
tage for OXC.
Only data of the SANAD trial were available for the analysis of
this outcome. There were no significant differences in time to 12-
month remission from seizures betweenCBZ andOXC (HR0.92,
95% CI 0.72 to 1.18 Analysis 1.4; Figure 4).
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Figure 4. Comparison OXC versus CBZ, Outcome 04 Time to 12-month remission from seizures.
Time to first seizure post-randomisation
For this outcome measure, a HR greater than 1 suggests an advan-
tage for CBZ.
Only data of the SANAD trial (Marson 2007) were available for
the analysis of this outcome. There were no significant differences
in time to first seizure post-randomisation betweenCBZ andOXC
(HR 1.06, 95% CI 0.84 to 1.33 Analysis 1.5; Figure 5).
Figure 5. Comparison OXC versus CBZ, Outcome 05 Time to first seizure post randomisation.
Adverse Events
For this outcome measure, an OR greater than 1 indicates an
advantage for CBZ.
There were no significant differences in the overall number of
adverse events between the two drugs (OR 0.87, 95% CI 0.64
to 1.18; Analysis 1.6; Figure 6). We included further analyses on
five common adverse events. There were no significant differences
betweenOXCandCBZ in the occurrence of allergic rash (Analysis
1.8; Figure 7), dizziness or vertigo (Analysis 1.9; Figure 8) and
headache (Analysis 1.10; Figure 9). There was a trend towards a
clinical advantage ofOXC in the occurrence of fatigue/drowsiness/
sedation (OR 0.67, 95% CI 0.43 to 1.07; Analysis 1.7; Figure
10) but this was not statistically significant (P = 0.09). There were
significantly fewer occurrences of nausea or vomiting, or both,
among patients using CBZ, which suggests a clinical advantage of
CBZ over OXC (OR 3.15, 95% CI 1.39 to 7.14 Analysis 1.11;
Figure 11).
Figure 6. Comparison OXC versus CBZ, Outcome 06 Overall Adverse Events.
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Figure 7. Comparison OXC versus CBZ, Outcome 08 Allergic Rash.
Figure 8. Comparison OXC versus CBZ, Outcome 09 Dizziness/Vertigo.
Figure 9. Comparison OXC versus CBZ, Outcome 10 Headache.
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Figure 10. Comparison OXC versus CBZ, Outcome 07 Fatigue/Drowsiness/Sedation.
Figure 11. Comparison OXC versus CBZ, Outcome 11 Nausea/Vomiting.
We detected no significant heterogeneity between the trials in any
of these analyses (Chi2 P > 0.10 in all analyses).
D I S C U S S I O N
The three randomised controlled trials included in this review
were unblinded. Only one trial used adequate outcome measures
of efficacy;therefore, the results pertaining to efficacy are based on
a single trial (Marson 2007).
With regard to the efficacy of the treatments, there were no signif-
icant differences between CBZ and OXC in the time to treatment
withdrawal (overall), in the time to treatment withdrawal due to
inadequate seizure control, in the time to the first seizure post ran-
domisation or in the time to 12-month remission from seizures.
The tolerability of the two treatments was comparable: there were
no significant differences in the time to treatment withdrawal due
to unacceptable adverse events, or in the overall number of adverse
events. Significantly fewer patients allocated to CBZ treatment
experienced nausea or vomiting, which suggests an advantage of
CBZ over OXC for this particular outcome.
In summary, our analyses suggest that CBZ and OXC have a sim-
ilar efficacy and tolerability in patients with partial onset seizures,
but the confidence intervals are wide and do not rule out the pos-
sibility of important differences existing. There is currently no ev-
idence to suggest that either drug is superior to the other.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
CBZ and OXC appear to be equally effective in the treatment of
partial onset seizures, and are equally well tolerated; but confidence
intervals are wide and do not exclude the possibility of important
differences existing. There is currently no evidence to suggest that
either drug is superior to the other. There was a significant advan-
tage of CBZ over OXC in the occurrence of nausea or vomiting
on treatment.
Implications for research
The analyses of efficacy and adverse events depend solely, and
largely respectively, on a single large trial which was not specifically
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designed to compare OXC and CBZ. While the two drugs appear
similar in efficacy and tolerability, the confidence intervals are
wide and do not rule out the possibility of important differences
between OXC and CBZ. Further studies comparing the efficacy
and tolerability of OXB and CBZ are justified.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dizdarer 2000
Methods Single-centre randomised controlled unblinded trial. Quasi-randomisation by alternately allocating
patients to CBZ and OXC
Participants Children under the age of 14 with a history of more than two partial onset seizures. Patients with
a structural brain lesion were excluded from the study
Interventions Either CBZ in increasing doses to 20 mg/kg/day after 3 to 4 days, or OXC to 30 mg/kg/day after
3 to 4 days
Outcomes Recurrence of seizures during follow-up. Number of adverse events
Notes
Risk of bias Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quasi-randomisation by alternately allocating
patients to CBZ or OXC





Methods Multicentre randomised controlled unblinded trial. Patients were randomised by a central ran-
domisation centre, using a computer program
Participants Previously untreated patients aged 6 to 16 years with a history of at least two unprovoked partial
seizures
Interventions Drug titration, initial maintenance dose and any increments or decrements were decided by the
clinician, like in everyday practice, aided by the prescribing information for the drug in question
Outcomes Difference in performance in the Computerised Visual Searching Task and several additional mea-
sures of psychomotor speed, alertness, memory, learning and non-verbal intelligence between base-
line and 6months. Number of patients remaining seizure free during follow-up. Number of adverse
events
Notes
Risk of bias Risk of bias
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Donati 2007 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation by a central randomisation cen-
tre, using a computer program





Methods Multicentre randomised controlled unblinded trial. Patients were randomised by a central ran-
domisation centre, using a computer program that used a minimisation procedure
Participants Children and adults above the age of 4 with a history of two or more definite unprovoked epileptic
seizures in the year previous to randomisation. CBZ deemed the better standard treatment option,
compared to valproate, by the recruiting physician. Patients were excluded if all seizures had been
acute symptomatic seizures, or if there was a history of progressive neurological disease
Interventions Drug titration, initial maintenance dose and any increments or decrements were decided by the
clinician, like in everyday practice, aided by guidelines
Outcomes Time to treatment withdrawal (overall). Time to treatment withdrawal for unacceptable adverse
events. Time to treatment withdrawal for inadequate seizure control. Time to 12-month remission
from seizures. Time to first seizure. Number of adverse events
Notes
Risk of bias Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation by a central randomisation cen-
tre, using a computer program
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dam 1989 Inclusion of patients with primary generalised seizures.
Reinikainen 1987 Inclusion of patients with primary generalised seizures.
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D A T A A N D A N A L Y S E S
Comparison 1. OXC versus CBZ




participants Statistical method Effect size
1 Time to treatment withdrawal
for any reason
1 588 Hazard Ratio (Fixed, 95% CI) 1.04 [0.78, 1.39]
2 Time to treatment withdrawal
for unacceptable adverse events
1 588 Hazard Ratio (Fixed, 95% CI) 0.85 [0.59, 1.24]
3 Time to treatment withdrawal
for inadequate seizure control
1 588 Hazard Ratio (Fixed, 95% CI) 1.33 [0.82, 2.15]
4 Time to 12-month remission
from seizures
1 588 Hazard Ratio (Fixed, 95% CI) 0.92 [0.72, 1.18]
5 Time to first seizure
post-randomisation
1 588 Hazard Ratio (Fixed, 95% CI) 1.06 [0.84, 1.33]
6 Overall Adverse Events 3 723 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.64, 1.18]
7 Fatigue/Drowsiness/Sedation 3 723 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.43, 1.07]
8 Allergic Rash 3 723 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.50, 1.43]
9 Dizziness/Vertigo 3 723 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.69, 2.50]
10 Headache 3 723 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.43, 1.78]
11 Nausea/Vomiting 3 723 Odds Ratio (M-H, Fixed, 95% CI) 3.15 [1.39, 7.14]
Analysis 1.1. Comparison 1 OXC versus CBZ, Outcome 1 Time to treatment withdrawal for any reason.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 1 Time to treatment withdrawal for any reason
Study or subgroup OXC CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Marson 2007 210 378 0.0392 (0.148) 100.0 % 1.04 [ 0.78, 1.39 ]
Total (95% CI) 210 378 100.0 % 1.04 [ 0.78, 1.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours OXC Favours CBZ
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Analysis 1.2. Comparison 1 OXC versus CBZ, Outcome 2 Time to treatment withdrawal for unacceptable
adverse events.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 2 Time to treatment withdrawal for unacceptable adverse events
Study or subgroup OXC CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Marson 2007 210 378 -0.161 (0.19) 100.0 % 0.85 [ 0.59, 1.24 ]
Total (95% CI) 210 378 100.0 % 0.85 [ 0.59, 1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours OXC Favours CBZ
Analysis 1.3. Comparison 1 OXC versus CBZ, Outcome 3 Time to treatment withdrawal for inadequate
seizure control.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 3 Time to treatment withdrawal for inadequate seizure control
Study or subgroup OXC CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Marson 2007 210 378 0.28517894 (0.2458) 100.0 % 1.33 [ 0.82, 2.15 ]
Total (95% CI) 210 378 100.0 % 1.33 [ 0.82, 2.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours OXC Favours CBZ
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Analysis 1.4. Comparison 1 OXC versus CBZ, Outcome 4 Time to 12-month remission from seizures.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 4 Time to 12-month remission from seizures
Study or subgroup OXC CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Marson 2007 210 378 -0.0832 (0.126) 100.0 % 0.92 [ 0.72, 1.18 ]
Total (95% CI) 210 378 100.0 % 0.92 [ 0.72, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours CBZ Favours OXC
Analysis 1.5. Comparison 1 OXC versus CBZ, Outcome 5 Time to first seizure post-randomisation.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 5 Time to first seizure post-randomisation
Study or subgroup OXC CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Marson 2007 210 378 0.0582 (0.117) 100.0 % 1.06 [ 0.84, 1.33 ]
Total (95% CI) 210 378 100.0 % 1.06 [ 0.84, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours OXC Favours CBZ
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Analysis 1.6. Comparison 1 OXC versus CBZ, Outcome 6 Overall Adverse Events.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 6 Overall Adverse Events
Study or subgroup OXC CBZ Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dizdarer 2000 8/26 16/26 12.4 % 0.28 [ 0.09, 0.88 ]
Donati 2007 31/55 17/28 11.0 % 0.84 [ 0.33, 2.11 ]
Marson 2007 100/210 183/378 76.6 % 0.97 [ 0.69, 1.36 ]
Total (95% CI) 291 432 100.0 % 0.87 [ 0.64, 1.18 ]
Total events: 139 (OXC), 216 (CBZ)
Heterogeneity: Chi2 = 4.20, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 0.91 (P = 0.36)
0.1 0.2 0.5 1 2 5 10
Favours OXC Favours CBZ
Analysis 1.7. Comparison 1 OXC versus CBZ, Outcome 7 Fatigue/Drowsiness/Sedation.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 7 Fatigue/Drowsiness/Sedation
Study or subgroup OXC CBZ Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dizdarer 2000 4/26 11/26 20.3 % 0.25 [ 0.07, 0.93 ]
Donati 2007 7/55 5/28 12.6 % 0.67 [ 0.19, 2.34 ]
Marson 2007 22/210 48/378 67.0 % 0.80 [ 0.47, 1.37 ]
Total (95% CI) 291 432 100.0 % 0.67 [ 0.43, 1.07 ]
Total events: 33 (OXC), 64 (CBZ)
Heterogeneity: Chi2 = 2.63, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 1.68 (P = 0.093)
0.1 0.2 0.5 1 2 5 10
Favours OXC Favours CBZ
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Analysis 1.8. Comparison 1 OXC versus CBZ, Outcome 8 Allergic Rash.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 8 Allergic Rash
Study or subgroup OXC CBZ Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dizdarer 2000 0/26 2/26 8.0 % 0.18 [ 0.01, 4.05 ]
Donati 2007 4/55 3/28 12.0 % 0.65 [ 0.14, 3.15 ]
Marson 2007 20/210 38/378 80.0 % 0.94 [ 0.53, 1.67 ]
Total (95% CI) 291 432 100.0 % 0.85 [ 0.50, 1.43 ]
Total events: 24 (OXC), 43 (CBZ)
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
0.1 0.2 0.5 1 2 5 10
Favours OXC Favours CBZ
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Analysis 1.9. Comparison 1 OXC versus CBZ, Outcome 9 Dizziness/Vertigo.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 9 Dizziness/Vertigo
Study or subgroup OXC CBZ Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dizdarer 2000 3/26 7/26 38.3 % 0.35 [ 0.08, 1.56 ]
Donati 2007 4/55 0/28 3.7 % 4.98 [ 0.26, 95.86 ]
Marson 2007 13/210 14/378 58.0 % 1.72 [ 0.79, 3.72 ]
Total (95% CI) 291 432 100.0 % 1.32 [ 0.69, 2.50 ]
Total events: 20 (OXC), 21 (CBZ)
Heterogeneity: Chi2 = 4.24, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 0.84 (P = 0.40)
0.1 0.2 0.5 1 2 5 10
Favours OXC Favours CBZ
Analysis 1.10. Comparison 1 OXC versus CBZ, Outcome 10 Headache.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 10 Headache
Study or subgroup OXC CBZ Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dizdarer 2000 0/26 0/26 Not estimable
Donati 2007 6/55 2/28 14.1 % 1.59 [ 0.30, 8.45 ]
Marson 2007 9/210 21/378 85.9 % 0.76 [ 0.34, 1.69 ]
Total (95% CI) 291 432 100.0 % 0.88 [ 0.43, 1.78 ]
Total events: 15 (OXC), 23 (CBZ)
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours OXC Favours CBZ
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Analysis 1.11. Comparison 1 OXC versus CBZ, Outcome 11 Nausea/Vomiting.
Review: Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures
Comparison: 1 OXC versus CBZ
Outcome: 11 Nausea/Vomiting
Study or subgroup OXC CBZ Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dizdarer 2000 1/26 0/26 7.3 % 3.12 [ 0.12, 80.12 ]
Donati 2007 0/55 0/28 Not estimable
Marson 2007 15/210 9/378 92.7 % 3.15 [ 1.36, 7.34 ]
Total (95% CI) 291 432 100.0 % 3.15 [ 1.39, 7.14 ]
Total events: 16 (OXC), 9 (CBZ)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.75 (P = 0.0060)
0.1 0.2 0.5 1 2 5 10
Favours OXC Favours CBZ
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 (epilep*)
#2 MeSH descriptor Epilepsy explode all trees
#3 (seizure*)
#4 MeSH descriptor Seizures explode all trees
#5 convulsion*
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 oxcarbazepi*
#8 (trilept*)
#9 (#7 OR #8)
#10 MeSH descriptor Carbamazepine explode all trees
#11 (tegret* ) or (carbamazepi*)
#12 (#10 OR #11)
#13 (#9 AND #12)
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#14 (#6 AND #13)
Appendix 2. MEDLINE (PubMed) search strategy
#1 (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized controlled trials[mh] OR random allocation[mh]
OR double-blind method[mh] OR single-blind method[mh] OR clinical trial[pt] OR clinical trials[mh] OR (“clinical trial”[tw]) OR
((singl*[tw] ORdoubl*[tw] OR trebl*[tw]OR tripl*[tw]) AND (mask*[tw] ORblind*[tw])) OR (“latin square”[tw]) OR placebos[mh]
OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR comparative study[mh] OR evaluation studies[mh] OR follow-
up studies[mh] OR prospective studies[mh] OR cross-over studies[mh] OR control*[tw] OR prospectiv*[tw] OR volunteer*[tw])
NOT (animal[mh] NOT human[mh])
#2 epilepsy[mh] OR epilep*[tw]
#3 seizures[mh] OR seizure*[tw]
#4 convulsion*[tw]
#5 2 OR 3 OR 4
#6 oxcarbazepine[mh] OR oxcarbazepine[tw] OR oxcarbazepi*[tw] OR trileptal[tw] OR trilept*[tw]
#7 carbamazepine[mh] OR carbamazepine[tw] OR carbamazepi*[tw] OR tegret*[tw]
#8 6 OR 7
#9 1 AND 5 AND 8
H I S T O R Y
Protocol first published: Issue 2, 2007
Review first published: Issue 4, 2009
C O N T R I B U T I O N S O F A U T H O R S
Marcus Koch and Susan Polman co-operated through all stages of assessing trials for inclusion, data extraction, data analysis and writing
of the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [adverse effects; ∗therapeutic use]; Carbamazepine [adverse effects; ∗analogs&derivatives; ∗therapeutic use]; Epilepsies,
Partial [∗drug therapy]; Randomized Controlled Trials as Topic
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MeSH check words
Humans
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